| HAIFA, Israel--(BUSINESS WIRE)--Sept. 5, 2006--Pluristem Life Systems,
Inc. (OTCBB:PLRS
- News) announces
CEO Zami Aberman will speak at the 2006 Biotech & Life Sciences Global
Venture Congress being held September 14 and 15 at Madison Square
Garden, New York City. Aberman will describe how their PLX line of
products has the potential to eliminate the current bone marrow
transplant search and match process. Dr. Gyan Parida, Chairman, Global
Venture Congress commented, "We are pleased to feature Pluristem as one
of our presenting companies at the Global Venture Congress. We consider
Pluristem a company that is imminently fundable. They were chosen to be
a featured presenting company because of their novel technology, history
of raising private capital, and their ability to maximize the capital
raised by bringing adult stem cells to the Phase I/II development stage.
Very impressive and commendable, Pluristem has passed our rigorous
screening process."
About Global Venture Congress
The Biotech & Life Sciences Global Venture Congress is designed to
explore the frontiers of biotech & life sciences, address the venture
capital landscape, identify current trends in innovation, learn
scientific discoveries and discover cutting-edge Biotech and Life
Sciences companies. Speakers are world renowned visionaries, carefully
chosen active investors in Biotech and Life Sciences companies,
founders/C-level executives of cutting edge Biotech companies and
renowned thought leaders, movers and shakers of the biotech industry and
analysts.
www.bio.saeclub.com
About Pluristem
Pluristem Life Systems, Inc. is a life sciences driven company that is
developing and commercializing stem cell expansion technology products
for the treatment of severe blood disorders. The Company is discovering
and developing cell-based therapeutics that utilizes adult stem cells
expanded in a proprietary bioreactor mimicking different naturally
occurring physiological environments. Pluristem expects its first
products to be cell grafts that will provide an efficient and superior
alternative to the standard procedure of bone marrow transplantation.
Its first adult stem cell product targets a critical global shortfall of
matched tissue for bone marrow transplantation since bone marrow
transplantation is often the only cure for patients suffering from
leukemia, lymphoma, myeloma and many other hematological diseases. The
Company has made a strategic decision to work only with adult stem cells
since the practical use of embryonic stem cells is severely restricted
by various religious, ethical and legal considerations.
www.pluristem.com/default.asp
www.pluristem.com
Safe Harbor Statement
This press release contains statements, which may constitute
"forward-looking statements" regarding our intent, belief or current
expectations. Forward-looking statements in this release include
statements: that Zami Aberman will be a featured speaker at the 2006
Biotech & Life Sciences Global Venture Congress; that Pluristem is
developing and commercializing stem cell expansion technology products
for the treatment of severe blood disorders, and is discovering and
developing cell-based therapeutics that utilizes adult stem cells
expanded in a proprietary bioreactor mimicking different naturally
occurring physiological environments; that Pluristem expects its first
products to be cell grafts that will provide an efficient and superior
alternative to the standard procedure of bone marrow transplantation,
targeting a critical global shortfall of matched tissue for bone marrow
transplantation. Factors which may significantly change or prevent our
forward looking statements from fruition include that the Congress may
not proceed; that Mr. Aberman may not be able to appear and speak for
some reason; that we may be unsuccessful in developing any products;
that our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; that we are
unable to retain or attract key employees whose knowledge is essential
to the development of our products; that unforeseen scientific
difficulties develop with our process; that results in the laboratory do
not translate to equally good results in real surgical settings; that
our patents are not sufficient to protect essential aspects of our
technology; that competitors may invent better technology; that our
products may not work as well as hoped or worse, that our products may
harm recipients; and that we may not be able raise funds for development
or working capital when we require it. As well, our products may never
develop into useful products and even if they do, they may not be
approved for sale to the public. For further risk factors see the
Company's latest 10-KSB filed with the SEC.
For more information visit our website at
www.pluristem.com
|
